 |
Rigel has signed partnerships with several leading pharmaceutical companies including, AstraZeneca, Pfizer, Merck, Johnson & Johnson, Novartis and Daiichi Sankyo. During our collaborations with many of these organizations, they added new programs or extended their relationship with Rigel beyond the scope of the initial agreements. To date Rigel has received over $260 million from collaborations. These partnerships are in addition to Rigel's own proprietary research and product development programs.
Current partnership summary:
DEVELOPMENT
PARTNER |
|
MECHANISM |
|
INDICATION |
|
YEAR |
|
|
|
|
AstraZeneca |
|
Syk inhibition - oral |
|
Rheumatoid arthritis |
|
2010 |
|
|
|
|
|
|
|
|
|
senior management
astrazeneca
